Ownership and insider activity for BeyondSpring Inc. (BYSI): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
BeyondSpring Inc. is a clinical-stage biopharmaceutical company focused on developing novel cancer treatments. Its flagship product is Plinabulin, a selective immune-modulating and microtubule-binding agent. Plinabulin has successfully advanced through Phase III clinical trials for two distinct applications: the prevention of chemotherapy-induced neutropenia, and the treatment of advanced non-small cell lung cancer.
Price
| Price | $0.71 |
| Market Cap | $29M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-07-01 | Majeti Jiangwen | A-Award | 100,000 | $175K |
| 2026-07-01 | Qiu Min | A-Award | 100,000 | $175K |
| 2026-07-01 | Qiu Min | |||
| 2026-07-01 | Li Na (NL) | |||
| 2026-03-20 | Huang Lan | G-Gift | 260,582 | |
| 2026-04-01 | Kirkby Matthew | A-Award | 23,902 | $39K |
| 2026-04-01 | Fabbio Patrick | A-Award | 22,165 | $36K |
| 2026-04-01 | Delaney Brendan | A-Award | 20,427 | $34K |
| 2026-04-01 | Majeti Jiangwen | A-Award | 21,730 | $36K |
| 2026-04-01 | Lu Yingjuan June | A-Award | 17,840 | $29K |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $11.7M | $27.5M | $3.9M | $35.9M | $109.5M | $41.6M | $34.4M | $15.3M | $2.9M | $7.8M |
| Short-term Investments | 0 | $3.1M | 0 | 0 | 0 | $30.7M | $2.9M | 0 | 0 | $4.8M |
| Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Inventory | $799000 | 0 | $1.2M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $14.7M | $32.3M | $5.9M | $40.9M | $113.4M | $75.1M | $38.5M | $18.4M | $28.6M | $20.9M |
| Property, Plant & Equipment | $80000 | $123000 | $282000 | $2.7M | $2.4M | $5.0M | $7.4M | $1.0M | $752000 | $471000 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $14.9M | $32.8M | $7.1M | $44.6M | $117.0M | $81.6M | $46.2M | $24.8M | $34.3M | $25.9M |
| Accounts Payable | $444000 | $3.4M | $9.6M | $2.5M | $2.2M | $1.7M | $1.1M | $561000 | $295000 | $363000 |
| Short-term Debt | $210000 | 0 | 0 | $29000 | 0 | $1.6M | 0 | $258000 | 0 | 0 |
| Total Current Liabilities | $2.6M | $4.8M | $16.4M | $10.1M | $13.8M | $15.2M | $7.4M | $8.0M | $11.0M | $13.6M |
| Long-term Debt | 0 | 0 | 0 | $1.4M | $2.2M | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | $2.6M | $4.8M | $16.4M | $13.4M | $25.2M | $60.7M | $49.2M | $48.3M | $48.6M | $49.9M |
| Retained Earnings | -$32.1M | -$123.9M | -$178.8M | -$216.8M | -$277.8M | -$342.0M | -$375.3M | -$396.3M | -$407.4M | -$408.4M |
| Total Equity | $12.2M | $27.1M | -$7.8M | $30.3M | $88.3M | $26.7M | -$6.0M | -$26.8M | -$32.9M | -$32.2M |
| Total Debt | $210000 | 0 | 0 | $3.9M | $4.3M | $3.6M | $5.0M | $847000 | $589000 | $320000 |
| Net Debt | -$11.5M | -$30.6M | -$3.9M | -$32.0M | -$105.2M | -$68.8M | -$32.3M | -$14.5M | -$2.3M | -$12.2M |
| Working Capital | $12.1M | $27.6M | -$10.6M | $30.8M | $99.6M | $60.0M | $31.2M | $10.5M | $17.6M | $7.3M |
Financial Health
| Debt / Equity | -0.00 |
| Current Ratio | 0.70 |
Profitability
| Return on Equity | 19.96% |
| Return on Invested Capital | -1429.62% |
| Return on Assets | -45.77% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ALXO · ATYR · BMEA · CAMP · DTIL · GUTS · HYFT
Explore sector: Healthcare · Biotechnology
More sections of BYSI: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks